The United Kingdom and the United States have hammered out a key commercial pact that will preserve no import taxes on British pharmaceutical shipments going into the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has committed to increase expenditure on drugs through the public health system. This pledge guarantees that tariffs on these vital goods will stay at zero for a period of three years.
This agreement is in response to recent threats to dramatically increase duties on patented drug products, with figures floated reaching one hundred percent.
"This agreement between the Britain strengthens the international landscape for new treatments and introduces much-needed fairness to American-British medicine commerce," a release noted.
Commercial Impact
Medicines represent one of the the United Kingdom's biggest exports to the United States, which is clearly the biggest destination for leading British pharmaceutical firms.
Export figures reveal that in the year to the end of last September, the UK sold pharmaceutical products worth billions to the US. This value accounted for 17.4% of British export trade in that timeframe.
"This guarantee protects jobs, stimulates capital expenditure and sets the stage for the UK to emerge as a international leader for biotech and pharma," the Business and Trade Secretary stated.
Key NHS Changes
The deal includes several key pledges from the United Kingdom:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a goal to increase total NHS spending on medicines from 0.3 percent of Gross Domestic Product to 0.6% over the coming ten years.
- Refund Ceiling: The percentage pharmaceutical firms must pay back to the NHS to prevent overspending will be capped at 15%. In the past, refunds exceeded twenty percent.
Recent Tensions
The deal follows a protracted dispute between the sector and the UK government over spending levels and approval rates.
These tensions were heightened by assertions that US customers were paying a premium for the equivalent treatments than consumers in the other developed nations.
Over the last 18 months, several large manufacturing plans in the UK have been delayed or abandoned, while substantial funding commitments have been announced toward US facilities.
The Science Minister publicly accepted that the NHS needed to spend more on drugs, noting that its budget allocation on drugs had declined as a share of its resources over the previous ten-year period.
